Novo Nordisk tests own mobile app in phase III trial with insulin hope

An internally-developed mobile app from Novo Nordisk will be part of a phase III trial involving the pharmaceutical company's grand hope insulin icodec. This app will help diabetes patients find their optimal insulin doses based on earlier doses and their blood sugar levels.

Photo: Tidsvilde Stine/Ritzau Scanpix

Novo Nordisk has started testing a hitherto-unknown app for people's phones which will help diabetes patients find their recommended doses based on their blood sugar levels and the insulin doses that they have already ingested, according to a report for the database Clinical Trials, which gathers info on clinical trials.

The name of the Mobile App is Doseguide, and Novo Nordisk tells MedWatch that this particular app was developed internally within the Danish pharmaceutical company. Novo Nordisk also confirms that the app advises patients to help them find the correct insulin doses.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs